
## Alessandro Perez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7510236/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATIONS
1	Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. Critical Reviews in Oncology/Hematology, 2022, 170, 103597.	2.0	19
2	BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning. Critical Reviews in Oncology/Hematology, 2022, 172, 103626.	2.0	6
3	Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses. Therapeutic Advances in Medical Oncology. 2021. 13. 175883592110180.	1.4	7
4	Not all <i>KIT</i> 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110497.	1.4	3
5	Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?. Oncology Research and Treatment, 2020, 43, 526-530.	0.8	16
6	CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020008.	0.5	14
7	The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors. Advances in Hematology, 2020, 2020, 1-5.	0.6	5
8	Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors. Chemotherapy, 2019, 64, 205-209.	0.8	10
9	Spheroids from adiposeâ€derived stem cells exhibit an miRNA profile of highly undifferentiated cells. Journal of Cellular Physiology, 2018, 233, 8778-8789.	2.0	20
10	EGFR inhibition in NSCLC: New findings…. and opened questions?. Critical Reviews in Oncology/Hematology, 2017, 112, 126-135.	2.0	22
11	Dietary restriction: could it be considered as speed bump on tumor progression road?. Tumor Biology, 2016, 37, 7109-7118.	0.8	24
12	A headlight on liquid biopsies: a challenging tool for breast cancer management. Tumor Biology, 2016, 37, 4263-4273.	0.8	18
13	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. Oncotarget, 2016, 7, 60712-60722.	0.8	103
14	Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?. Analytical Cellular Pathology, 2015, 2015, 1-19.	0.7	80